Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Celiac Disease Prevention
This study is currently recruiting participants.
Verified by Kuopio University Hospital, August 2008
Sponsors and Collaborators: Kuopio University Hospital
University of Kuopio
University of Turku
National Public Health Institute
Päivikki and Sakari Sohlberg Foundation
Information provided by: Kuopio University Hospital
ClinicalTrials.gov Identifier: NCT00617838
  Purpose

Celiac disease is an autoimmune disease induced by wheat gluten. Destruction of epithelial cells and microvilli on gut mucosa is causing a "flat mucosa" and an absorption defect. The diagnosis is based on typical microscopical finding in biopsy specimens but serum antibodies to tissue transglutaminase and certain gliadin peptides are strongly associated with the pathology. Severe diarrhoea associated with growth disturbance in infancy was historically characterising the disease but is nowadays rare. Clinically more mild forms including silent disease are very common. Studies based on antibody screening and biopsies done in autoantibody positive subjects have confirmed a frequency of about 1-2% in adult population. Undiagnosed disease is associated with deficiencies of nutrients and vitamins leading to various chronic symptoms like anaemia, osteoporosis and general fatigue. It has also been recently found that undiagnosed celiac disease may be associated with general underachievement in society probably associated with common psychological symptoms like fatigue and depression during the adolescence. The disease is treated by complete elimination of wheat, rye and barley in the diet, which is laborious and causing considerable extra costs in nutrition.

Much progress has been recently made in understanding of the genetic background and immune markers associated with the disease as well as in understanding those patterns of gluten introduction in infancy, which might be connected to a high disease risk. Our aim in this study is in the first phase to identify children at high genetic risk (around 10%) and in a follow-up study to define:

  1. Are the age, dose of gluten and presence of simultaneous breast feeding at the introduction of gluten associated with the risk of celiac disease?
  2. Is it possible to decrease the frequency of celiac disease by nutritional counselling?
  3. Is it possible to predict development of celiac disease by immunological tests before the development of mucosal lesion

If we can confirm, that optimising the conditions at the introduction of wheat gluten in infancy diet significantly reduces the disease incidence, will this have an important effect on the nutritional recommendations concerning the diet in infancy. Combining genetic screening and immunological tests might also offer a way to reduce the frequency of celiac disease and help in early diagnosis and organisation of an adequate treatment


Condition Intervention
Celiac Disease
Other: Optimal gluten introduction

MedlinePlus related topics: Celiac Disease
Drug Information available for: Immunoglobulins Globulin, Immune
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Single Blind (Subject), Parallel Assignment
Official Title: Prevention of Celiac Disease in Children at Genetic Risk - Optimized Introduction of Gluten and Follow-up of Immunization

Further study details as provided by Kuopio University Hospital:

Primary Outcome Measures:
  • development of transglutaminase antibodies [ Time Frame: 2-4 year age ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • gliadin peptide antibodies [ Time Frame: 2-4 years ] [ Designated as safety issue: No ]
  • mucosal biopsy in TGA positive childre [ Time Frame: 2-4 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 316
Study Start Date: October 2007
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
Optimization of gluten introduction by nutritional councelling
Other: Optimal gluten introduction
Optimization of gluten introduction by nutritional counselling
2: No Intervention
No specific nutritional councelling. Follow-up of gluten introduction

  Eligibility

Ages Eligible for Study:   up to 2 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Presence of HLA-risk alleles DQA1*05 and DQB1*02

Exclusion Criteria:

  • Lack of these HLA risk alleles
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00617838

Contacts
Contact: Anne Bjork, MSc +358 17 173311 anne.bjork@kuh.fi

Locations
Finland
Kuopio University Hospital Recruiting
Kuopio, Finland, FIN-70211
Principal Investigator: Pekka Arikoski, ID            
Sponsors and Collaborators
Kuopio University Hospital
University of Kuopio
University of Turku
National Public Health Institute
Päivikki and Sakari Sohlberg Foundation
Investigators
Principal Investigator: Jorma Ilonen, MD University of Kuopio
  More Information

Responsible Party: University of Kuopio ( Jorma Ilonen/ Professor )
Study ID Numbers: KUH5021612
Study First Received: February 6, 2008
Last Updated: August 7, 2008
ClinicalTrials.gov Identifier: NCT00617838  
Health Authority: Finland: Ethics Committee

Keywords provided by Kuopio University Hospital:
Celiac disease
genetic risk
gluten introduction
predicting antibodies

Study placed in the following topic categories:
Antibodies
Metabolic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Malabsorption Syndromes
Celiac Disease
Metabolic disorder
Intestinal Diseases
Immunoglobulins

ClinicalTrials.gov processed this record on January 14, 2009